Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort

Table 2 Measures of adherence to CVD prevention guidelines

Adherence category	Total (n = 309)	Primary prevention (n = 204)	Secondary prevention (n = 105)	P value
Lifestyle adherence
Recommended diet^a	159 (52.7 %)	105 (52.2 %)	54 (53.5 %)	0.84
Non-smoking	296 (95.8 %)	195 (95.6 %)	101 (96.2 %)	0.80
Physically active	217 (70.5 %)	154 (75.5 %)	63 (60.6 %)	0.007*
Clinical target attainment
HbA1c ≤7.0 %	103 (35.0 %)	74 (38.1 %)	29 (29.0 %)	0.12
Blood pressure ≤130/80 mmHg^b	76 (47.8 %)	53 (50.5 %)	23 (42.6 %)	0.35
LDL-C ≤ 2.0 mmol/L	150 (57.7 %)	95 (54.6 %)	55 (64.0 %)	0.15
Optimal BMI <25.0 kg/m²	149 (50 %)	101 (51.0 %)	48 (48.0 %)	0.62
Pharmacotherapy adherence
RAS inhibitor^c	221 (72.5 %)	144 (72.0 %)	77 (73.3 %)	0.80
Statin	220 (72.1 %)	131 (65.5 %)	89 (84.8 %)	<0.001*
Among participants Age <75^d	190 (72.0 %)	117 (65.0 %)	73 (86.9 %)	<0.001*
Total adherence
Median percentage of targets met	62.5 (50.0, 75.0)	62.5 (50.0, 75.0)	62.5 (50.0, 77.8)	0.93

Data presented as proportion n (%) achieving adherence, calculated as percentage of available data. P values for comparison are calculated using the Mann–Whitney U or χ²-test, depending on variable distribution
^aRecommended diet measured by self-reported consumption of fruits and vegetables in addition to moderate consumption of dietary carbohydrates and fats
^bMissing blood pressure: 150 (49 %) missing
^cRASi includes usage of at least one of ARB and ACEi, percentages calculated out of only for participants who are eligible for RASi (see Methods)
^dStatin use percentages calculated out of only participants under age 75 (n = 264), instead of whole cohort (n = 309)
* Statistically significant p < 0.05

ISSN: 1475-2840